Curcumin and PPIs have comparable efficacy for functional dyspepsia

Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-10-05 14:30 GMT   |   Update On 2023-10-05 14:30 GMT

Functional dyspepsia is one of the major causes of upper abdominal discomfort. The condition affects 5-10% of the world population. Nearly 50 % of the patients seek alternative treatments to manage the condition. A recent study published in BMJ Evidence-Based Medicine has demonstrated the potential of curcumin in treating patients with functional dyspepsia. Researchers in this study...

Login or Register to read the full article

Functional dyspepsia is one of the major causes of upper abdominal discomfort. The condition affects 5-10% of the world population. Nearly 50 % of the patients seek alternative treatments to manage the condition. A recent study published in BMJ Evidence-Based Medicine has demonstrated the potential of curcumin in treating patients with functional dyspepsia. Researchers in this study proved efficacy to be “comparable” for curcumin and omeprazole, a proton pump inhibitor.

In this double-blind, randomised trial, researchers evaluated the efficacy of curcumin compared with omeprazole for managing functional dyspepsia. 206 patients were treated with curcumin, omeprazole, or curcumin plus omeprazole. There was significant improvement in the three groups. No significant differences among the three groups related to symptom improvement were recorded. Synergism was not reported between omeprazole and curcumin.

The study was conducted in Thai traditional medicine hospitals, district hospitals, and university hospitals in Thailand. Participants included had a diagnosis of functional dyspepsia. Intervention included curcumin alone (C), omeprazole alone (O), or curcumin plus omeprazole (C+O). The combination group patients received two capsules of 250 mg curcumin four times daily and one capsule of 20 mg omeprazole once daily for 28 days.

The severity of Dyspepsia Assessment (SODA) score was used to measure the functional dyspepsia symptoms on days 28 and 56. Secondary outcomes included adverse events and serious adverse events.

Key results of the study are:

  • One hundred fifty-one participants completed the study.
  • Demographic data, clinical characteristics and baseline dyspepsia scores were comparable between the three groups.
  • There were Significant improvements in SODA scores on day 28 in pain (−4.83, –5.46 and −6.22), non-pain (−2.22, –2.32 and −2.31) and satisfaction (0.39, 0.79 and 0.60) categories for the C+O, C, and O groups, respectively.
  • On day 56, these improvements were enhanced in pain (−7.19, –8.07 and −8.85), non-pain (−4.09, –4.12 and −3.71) and satisfaction (0.78, 1.07, and 0.81) categories in three groups.
  • No significant differences or serious adverse were reported.

Concluding further, this study found the presence of comparable efficacy between Curcumin and omeprazole for functional dyspepsia.

We found no obvious synergistic effect between curcumin and omeprazole, they noted.

Reference:

Kongkam P, et al Curcumin and proton pump inhibitors for functional dyspepsia: a randomised, double-blind controlled trial BMJ Evidence-Based Medicine Published Online First: 11 September 2023. doi: 10.1136/bmjebm-2022-112231


Tags:    
Article Source : BMJ Evidence-Based Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News